Scott Buck

NS Pharma, Inc. (NSP) located in Paramus New Jersey is a subsidiary of Nippon Shinyaku Co., Ltd. Founded in 1999 in the United States, NSP is engaged in clinical studies and partnering with global pharmaceutical companies, venture companies and research institutes. NSP serves as a contact point for connecting Japan/Asia and the world, developing drug candidates invented in Japan and out-license them to the world. From the world to Japan/Asia, NSP in-license promising drug candidates to the Japanese/Asian Markets. In coordination with parent company, Nippon Shinyaku, Co., Ltd., NSP will first and foremost develop and supply safe and highly effective pharmaceuticals through clinical studies. NSP aims to be an indispensable entity in the healthcare industry in line with the guidelines for action “Challenge”, “Speed”, and “Investigation”.